Y Intercept Hong Kong Ltd Makes New Investment in Mirum Pharmaceuticals, Inc. $MIRM

Y Intercept Hong Kong Ltd bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 3rd quarter, Holdings Channel reports. The fund bought 11,025 shares of the company’s stock, valued at approximately $808,000.

Other institutional investors have also bought and sold shares of the company. Comerica Bank grew its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter. CWM LLC grew its holdings in Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares in the last quarter. Osaic Holdings Inc. raised its position in shares of Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after buying an additional 351 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 14.9% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock worth $97,000 after buying an additional 248 shares in the last quarter. Finally, Longboard Asset Management LP bought a new position in shares of Mirum Pharmaceuticals during the third quarter worth $214,000.

Wall Street Analyst Weigh In

Several analysts have commented on MIRM shares. Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. HC Wainwright boosted their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Finally, Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.25.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 6,831 shares of the firm’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $657,073.89. Following the completion of the sale, the chief executive officer owned 169,402 shares of the company’s stock, valued at approximately $16,294,778.38. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 842 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $80,991.98. Following the sale, the senior vice president owned 3,700 shares in the company, valued at $355,903. The trade was a 18.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 32,429 shares of company stock worth $3,039,396. 14.36% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Stock Up 0.6%

NASDAQ:MIRM opened at $103.80 on Tuesday. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $105.11. The company’s 50-day simple moving average is $80.92 and its 200-day simple moving average is $72.95. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The stock has a market capitalization of $5.33 billion, a P/E ratio of -120.70 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.30) earnings per share. On average, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.